Search clinical trials for: Anti PD-1

Total 186571 results

Akeso
Akeso Pharmaceuticals, Inc.

Completed

A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Memorial Sloan Kettering Cancer Center
AstraZeneca; Marker Therapeutics, Inc.

Completed

TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer

Ovarian Cancer

United States
University of Leipzig

Recruiting

Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors (CaPture)

Hepatocellular Carcinoma

Germany
Beijing Friendship Hospital
Changhai Hospital; Peking Union Medical College Hospital; Peking University Cancer...

Not yet recruiting

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Locally Advanced Rectal Cancer

China
Aarhus University Hospital

Completed

Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients

Malignant Melanoma

Denmark
Changhai Hospital
National Natural Science Foundation of China

Completed

PD-1/PD-L1 Pathway Study on Septic Patients

Sepsis
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Camrelizumab(SHR-1210) Combined With Apatinib in the Treatment of Advanced Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Symphogen A/S

Completed

Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Lymphoma | Solid Tumor | Metastatic Cancer

Canada, United States
Junling Li

Recruiting

Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy

Advanced Non Squamous NSCLC

China
NYU Langone Health
Bristol-Myers Squibb

Completed

Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

Melanoma

United States
Akeso

Not yet recruiting

A Phase II Study of AK104 for Recurrent or Metastatic Vulvar Cancer

Vulvar Cancer

China
Di Wu

Not yet recruiting

Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma

Undifferentiated Pleomorphic Sarcoma | Soft Tissue Sarcomas

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs

Unresectable Gallbladder Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

A Clinical Study of a Preoperative Translational Therapy for Unresectable Gallbladder Cancer

Unresectable Gallbladder Cancer

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma

Chondrosarcoma

China
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial (MAGIC)

Multiple Primary Lung Cancer

China
Shi Ming

Withdrawn

Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria

Hepatocellular Carcinoma

China
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; The First Affiliated Hospital... and other collaborators

Withdrawn

Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC

Hepatocellular Carcinoma

China
Sun Yat-sen University

Withdrawn

Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC

Hepatocellular Carcinoma

China
CellSight Technologies, Inc.
Stanford University

Completed

Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Squamous Cell Carcinoma of the Head and Neck

United States
The First Affiliated Hospital of Soochow University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT

Acute Myeloid Leukemia

China
Merck Sharp & Dohme LLC

Recruiting

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

Advanced Solid Tumors | Metastatic Solid Tumors

Canada, Switzerland, United States
Sun Yat-sen University

Recruiting

Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer

Colorectal Cancer Stage IV | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
Fuda Cancer Hospital, Guangzhou
Shenzhen Hank Bioengineering Institute

Completed

Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors

Malignant Solid Tumour

China
Merck Sharp & Dohme LLC

Completed

Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)

Head and Neck Squamous Cell Cancer
Elpiscience Biopharma, Ltd.

Terminated

A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors

Neoplasms | Solid Tumors | Malignant Tumor

China
West China Hospital

Recruiting

Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

BRAF V600E-mutated /MSS Metastatic Colorectal Cancer | Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody

China
Jiangsu HengRui Medicine Co., Ltd.
Shanghai Chest Hospital

Unknown

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Chemotherapy Effect | KRAS Gene Mutation | NSCLC Stage IV | PD-1 Antibody
National Institute for Tuberculosis and Lung Diseases...

Suspended

Coorticosteroid Regimen in Patients With Anti-PD-1/PD-L1 Induced Pneumonitis (PROS-CONS)

Interstitial Lung Disease | Lung Neoplasm Malignant

Poland
Incyte Corporation

Active, not recruiting

Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

Melanoma

United States, Australia
Apexigen America, Inc.
Bristol-Myers Squibb

Completed

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

Melanoma | Cancer | Metastatic Melanoma | Non Small Cell Lung Cancer Metastatic | Neoplasm of Lung

United States, Spain
Providence Health & Services
Bristol-Myers Squibb; Exelixis

Active, not recruiting

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Refractory Cutaneous Melanoma

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab (Mel64)

Melanoma

United States
Agenus Inc.

Recruiting

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Melanoma | Ovarian Cancer | Prostate Cancer | Non-small-cell Lung Cancer | Endometrial Cancer | Advanced Cancer | Angiosarcoma | Fibrolamellar Carcinoma | Colorectal Cancer Without Liver Metastases

United States
John Mascarenhas
Massachusetts General Hospital; Montefiore Medical Center

Completed

PD-1 Inhibition in Advanced Myeloproliferative Neoplasms

Primary Myelofibrosis | Polycythemia Vera | Post-essential Thrombocythemia Myelofibrosis | Chronic Phase Myelofibrosis

United States
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients

Anal Canal Cancer | Anal Squamous Cell Carcinoma | Anal Cancer | Anal Canal Cancer Stage III

China
Chongqing University Cancer Hospital

Recruiting

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

Nasopharyngeal Carcinoma

China
Hadassah Medical Organization

Recruiting

Adjustment of Aminoglycoside Dosing Based on Peak Serum Concentration and Bacterial Minimal Inhibitory Concentration

Aminoglycoside Dosing Based on PK/PD Characteristics

Israel
iOx Therapeutics
Merck Sharp & Dohme LLC

Terminated

IMM60 and Pembrolizumab in Melanoma and NSCLC

Melanoma | Non-small Cell Lung Cancer

Spain, United States, United Kingdom
Incyte Corporation
Zai Lab (Shanghai) Co., Ltd.

Active, not recruiting

Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (POD1UM-304)

Metastatic Squamous Non-Small Cell Lung Cancer | Metastatic Nonsquamous Non-Small Cell Lung Cancer

China, Czechia, Russian Federation, Serbia, Malaysia, Vietnam, United States, Poland, Ukraine, Romania, Turkey, Brazil, Bulgaria, Georgia, Hungary, Philippines, South Africa
Genzyme, a Sanofi Company
Diacrin/Genzyme Corporation LLC

Completed

Phase 2, Double-blind, Randomized, Controlled Multi-center Clinical Trial of the Safety and Efficacy of Transplanted Fetal Porcine Cells in Patients With Parkinson's Disease.

Parkinson's Disease

United States
Chinese PLA General Hospital

Unknown

Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs

Primary Mediastinal Large B-cell Lymphoma

China
AnaptysBio, Inc.

Recruiting

A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)

Ulcerative Colitis

United States, Georgia
Shenzhen Geno-Immune Medical Institute

Recruiting

Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

Sarcoma | Ewing Sarcoma | Osteoid Sarcoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer

Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer

Esophageal Cancer

China
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)

Gastric Adenocarcinoma
Bristol-Myers Squibb

Completed

A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy

Melanoma

United States
Neuraly, Inc.

Active, not recruiting

A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

Parkinson Disease

United States, Canada
Merck Sharp & Dohme LLC
Gilead Sciences

Recruiting

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

Carcinoma, Non-Small-Cell Lung

China, Poland, Latvia, United States, Taiwan, Australia, Turkey, Germany, Israel, Korea, Republic of, Estonia, Romania, Chile, Italy, Brazil, Greece, Philippines, Canada, Japan, Malaysia, United Kingdom, Lithuania, Thailand, Peru

Search clinical trials for: Anti PD-1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations